CD274 and cancer: Cancer immunotherapies designed to target programmed death-1 (PD1)/PDL1 signaling showed antitumor responses in many cancers (including melanoma, non–small cell lung cancer, and various carcinomas); however, successful, durable, and long-lasting therapeutic responses are not experienced by all patients (13).